Modular Medical Inc. (MODD): The stock surged 30.68% to $0.9150 after announcing the completion of a clinical study for its MODD1 insulin pump and plans to submit its Pivot pump to the FDA in October 2025, alongside significant insider buying activity.
Galectin Therapeutics Inc. (GALT): The stock rose over 14% to $6.78, continuing a year-to-date gain of over 360%, with CEO Joel Lewis indicating ongoing analysis of biomarkers for their lead candidate, belapectin, which targets MASH cirrhosis and portal hypertension.
Exicure Inc. (XCUR): Shares increased 11.11% to $4.00 despite no new announcements, following a wider net loss reported for Q2 2025, as the company pivots its focus to new clinical directions after acquiring GPCR USA.
BioSig Technologies Inc. (BSGM): The stock gained 37.08% to $6.10, with an additional rise after announcing its rebranding to Streamex Corp. and a shift in focus towards real-world asset tokenization, including a partnership to develop tokenized gold products.
Wall Street analysts forecast GALT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GALT is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast GALT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GALT is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.150
Low
6.00
Averages
6.00
High
6.00
Current: 3.150
Low
6.00
Averages
6.00
High
6.00
H.C. Wainwright
Matthew Keller
Buy
maintain
$6 -> $11
Al Analysis
2025-12-17
Reason
H.C. Wainwright
Matthew Keller
Price Target
$6 -> $11
Al Analysis
2025-12-17
maintain
Buy
Reason
H.C. Wainwright analyst Matthew Keller raised the firm's price target on Galectin Therapeutics to $11 from $6 and keeps a Buy rating on the shares. The firm says recent biomarker data continue to strengthen confidence in Galectin's metabolic dysfunction-associated steatohepatitis program.
H.C. Wainwright
H.C. Wainwright
Buy
initiated
$6
2025-06-18
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$6
2025-06-18
initiated
Buy
Reason
H.C. Wainwright assumed coverage of Galectin Therapeutics with a Buy rating and $6 price target. Galectin's lead asset is belapectin, an intravenously administered galectin-3 inhibitor. Galectin-3 is a protein that plays a key role in cell signaling, differentiation, apoptosis, and inflammation, the analyst tells investors in a research note. The firm says that despite the company's setbacks, it believes "the stock can get back on track." It says belapectin is a "unique therapy targeting a clinically relevant molecule."
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GALT
Unlock Now
HC Wainwright & Co.
Ed Arce
Hold
Reiterates
n/a
2025-04-02
Reason
HC Wainwright & Co.
Ed Arce
Price Target
n/a
2025-04-02
Reiterates
Hold
Reason
About GALT
Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
